Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News
Skip to content
J Genberg - Kinnear Pharmaceuticals J Genberg - Kinnear Pharmaceuticals

Kinnear Pharmaceuticals


  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News

Kinnear Pharmaceuticals

Author: J Genberg

FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF

Posted on August 25, 2023 by J Genberg

FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a subsidiary of N8 Medical, Inc. today announced the U.S. Food

Read More
Uncategorized
Built with BoldGridPowered By DreamHost
Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News

©2019 Kinnear Pharmaceuticals, LLC